Paul Tappenden

BA (Nottingham Trent), MSc (Sheffield), PhD (Sheffield)

School of Medicine and Population Health

Professor of Health Economic Modelling

p.tappenden@sheffield.ac.uk
+44 114 222 0855
+44 114 222 0749 (Fax)
Regent Court (ScHARR)

Full contact details

Paul Tappenden
School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Profile

I have over 17 years’ experience in designing, developing and critically appraising health economic models across a wide range of disease areas. Since joining ScHARR in 2000, I have been involved in the assessment of numerous health technologies for the National Institute for Health and Care Excellence (NICE), including beta-interferon and glatiramer-acetate for multiple sclerosis, anti-TNFs for ulcerative colitis, inhaled therapies for cystic fibrosis and TKIs for medullary thyroid cancer. I have also undertaken modelling assessments for the National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Advisory Group for National Specialised Services (AGNSS), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. In 2011, I completed an NIHR-funded fellowship evaluating the role and value of health economic models of whole disease and treatment pathways (Whole Disease Modelling).

Research interests

My main research interests are:

  • Health economic modelling
  • Conceptual modelling
  • Whole disease modelling

Current projects

  • Technology assessments to inform the NICE Technology Appraisal Programme (various)
  • Economic analysis of interventions to improve adherence to nebulised therapies in patients with cystic fibrosis (alongside the CF ACtiF trial)
  • Modelling the potential cost-effectiveness of interventions for amyotrophic lateral sclerosis (part of the ALS-CARE study)
Publications

Show: Featured publications All publications

Journal articles

  • Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) . PharmacoEconomics, 34(10), 1023-1038.
  • Tappenden P & Chilcott J (2014) . Value in Health, 17(7), A585-A585.
  • Tappenden P & Chilcott JB (2014) . Pharmacoeconomics, 32(10), 967-979.
  • Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C & Brownlee K (2014) . PHARMACOECONOMICS, 32(2), 159-172.
  • Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S , Mavranezouli I et al (2013) . Health Technol Assess, 17(58), v-192.
  • Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C & Cantrell A (2013) . Health Technol Assess, 17(56), v-181.
  • Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) . Value in Health.
  • Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) . Value Health, 15(8), 1127-1136.
  • Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A (2010) . Health Technol Assess, 14(25), iii-107.
  • Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) . Bone Marrow Transplant, 45(6), 1014-1021.
  • Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) . Int J Technol Assess Health Care, 25(4), 470-478.
  • Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R & Nicholson K (2009) . Health Technol Assess, 13(11), iii-246.
  • Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD & Brown M (2009) . Value Health, 12(5), 657-665.
  • Tappenden P, Jones R, Paisley S & Carroll C (2007) . Eur J Cancer, 43(17), 2487-2494.
  • Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H & Karnon J (2007) . Gut, 56(5), 677-684.

All publications

Journal articles

  • Tappenden P, Cooper K, Hamilton J, Nalbant G, Essat M, Rayner A, Wong R, Battisti NML, Wyld L & Asghar U (2025) . Health Technology Assessment, 29(49).
  • Bageta ML, Lopez-Balboa P, Bursnall M, Glover R, Hutchence K, Papaioannou D, Biggs K, Julious S, Wilson I, Tappenden P , Turton E et al (2025) . EClinicalMedicine.
  • Bageta ML, López-Balboa P, Dimairo M, Glover R, Hutchence K, Papaioannou D, Cooper C, Biggs K, Tappenden P, Ennis K , Ogboli M et al (2025) . BMJ Open, 15(5).
  • Cooper K, Nalbant G, Essat M, Harnan S, Wong R, Hamilton J, Asghar US, Battisti NML, Wyld L & Tappenden P (2025) . Breast Cancer Research and Treatment, 210(2), 229-247.
  • Alshreef A, Latimer N, Tappenden P & Dixon S (2025) . Medical Decision Making, 45(1), 60-73.
  • Ren S, Singh J, Gsteiger S, Reed B, Cogley CM, Abrams K, Dawoud D, Owen R, Tappenden P, Quinn T & Bujkiewicz S (2024) . Value in Health, 27(12), S623-S623.
  • Lister J, Paisley S, Carroll C & Tappenden P (2024) . PharmacoEconomics, 42(11), 1255-1266.
  • Tappenden P, Hardiman O, Kwon S-H, Mon-Yee M, Galvin M & McDermott C (2024) . PharmacoEconomics, 42(9), 1003-1016.
  • Keetharuth AD, Gould R, McDermott C, Thompson B, Rawlinson C, Bradburn M, Bursnall M, Kumar P, Turton E, Tappenden P , White D et al (2024) . European Journal of Neurology, 31(8).
  • Wheaton L, Poad H, Tappenden P & Bujkiewicz S (2023) . Value in Health, 26(12), S425-S425.
  • Lister J, Paisley S, Tappenden P & Carroll C (2023) . Value in Health, 26(12), S375-S375.
  • Lister J, Paisley S, Tappenden P & Carroll C (2023) . Value in Health, 26(12), S174-S175.
  • Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) . Journal of Thoracic Oncology, 18(11), S134-S134.
  • Umemneku-Chikere CM, Wheaton L, Poad H, Ray D, Andrade IC, Khan S, Tappenden P, Abrams KR, Owen RK & Bujkiewicz S (2023) . Journal of Clinical Epidemiology, 164, 96-103.
  • Jin H, Tappenden P, Ling X, Robinson S & Byford S (2023) . PLOS ONE, 18(9).
  • Tappenden P, Navega Biz A, Hernández Alava M, Sasso A, Sutton L, Ennis K, Elliott R & Wildman M (2023) . International Journal of Technology Assessment in Health Care, 39(1).
  • Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A , Wright K et al (2022) . Health Technology Assessment, 25(76), 1-228.
  • Wildman MJ, O'Cathain A, Maguire C, Arden MA, Hutchings M, Bradley J, Walters SJ, Whelan P, Ainsworth J, Buchan I , Mandefield L et al (2022) . Thorax, 77(5), 461-469.
  • Wildman MJ, O’Cathain A, Hind D, Maguire C, Arden MA, Hutchings M, Bradley J, Walters SJ, Whelan P, Ainsworth J , Tappenden P et al (2021) . Programme Grants for Applied Research, 9(11), 1-146.
  • Srivastava T, Latimer NR & Tappenden P (2021) . PharmacoEconomics, 39(8), 869-878.
  • Jin H, Tappenden P, MacCabe JH, Robinson S, McCrone P & Byford S (2021) . The British Journal of Psychiatry, 218(4), 224-229.
  • Burt RK, Tappenden P, Balabanov R, Han X, Quigley K, Snowden JA & Sharrack B (2021) . Frontiers in Neurology, 12.
  • Cooper K, Tappenden P, Cantrell A & Ennis K (2020) . British Journal of Cancer, 123(11), 1686-1696.
  • Burt RK, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, Snowden JA & Hartung D (2020) . Multiple Sclerosis and Related Disorders, 45, ---.
  • Jin H, Tappenden P, Robinson S, Achilla E, Aceituno D & Byford S (2020) . PLOS ONE, 15(7).
  • Jin H, Tappenden P, Robinson S, Achilla E, MacCabe JH, Aceituno D & Byford S (2020) . PharmacoEconomics, 38(6), 537-555.
  • Jin H, Tappenden P, MacCabe JH, Robinson S & Byford S (2020) . JAMA network open, 3(5).
  • Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D & Snowden JA (2020) . Bone Marrow Transplantation, 55(7), 1473-1475.
  • Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J & Dixon S (2019) . Medical Decision Making, 39(8), 910-925.
  • Tappenden P & Caro JJ (2019) . PharmacoEconomics, 37(11), 1303-1304.
  • Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) . Health Technology Assessment, 23(30).
  • Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, Moss L & Balasubramanian S (2019) . Health Technology Assessment, 23(8), 1-144.
  • Tappenden P, Carroll C, Stevens J, Simpson E, Thokala P, Wong R, Wright J & Auer R (2019) . Pharmacoeconomics, 37(1), 7-18.
  • Tappenden P, Simpson E, Hamilton J, Pollard D, Clowes M, Kaltenthaler E, Meiklejohn D & Morley N (2019) . PharmacoEconomics, 37(3), 333-343.
  • Wildman M, Hutchings M, Arden M, O'Cathain A, Drabble S, Walters SJ, Tappenden P, Beever D, Whelan P, Bradley J , Cantrill H et al (2018) .
  • Bermejo I, Tappenden P & Youn JH (2017) . PharmacoEconomics, 35(11), 1189-1190.
  • Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F & Ghazavi M (2017) . PharmacoEconomics, 35(8), 805-815.
  • Bermejo I, Tappenden P & Youn JH (2017) . Pharmacoeconomics, 35, 1113-1121.
  • Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D & Tappenden P (2017) . PharmacoEconomics , 35(7), 717-726.
  • Tappenden P, Sadler S & Wildman M (2017) . PharmacoEconomics, 35(6), 647-659.
  • Carroll C, Kaltenthaler E, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2017) . Value in Health, 20(6), 785-791.
  • Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A , Perera S et al (2017) . Health Technol Assess, 21(25), 1-536.
  • Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2017) . PharmacoEconomics, 35(5), 537-547.
  • Harnan SE, Essat M, Gomersall T, Tappenden P, Pavord I, Everard M & Lawson R (2017) . Clinical and Experimental Allergy, 47(3), 410-429.
  • Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S & Tidy J (2016) . PharmacoEconomics.
  • Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) . PharmacoEconomics, 34(10), 1023-1038.
  • Thokala P, Simpson E, Tappenden P, Stevens J, Dickinson K, Ryder S & Harrison P (2016) . PharmacoEconomics, 34(8), 741-750.
  • Sadler S, Wildman M & Tappenden P (2016) . Journal of Cystic Fibrosis, 15, S119-S120.
  • Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A & Hoque S (2016) . Health Technoogyl Assessment, 20.
  • Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) . Health Technology Assessment, 20.
  • Gomersal T, Harnan S, Essat M, Tappenden P, Wong R, Lawson R, Pavord I & Everard ML (2016) . Pediatric Pulmonology, 51(3), 316-328.
  • Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I, Lawson R & Everard M (2016) . European Respiratory Society.
  • Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, Lobo A & Hoque S (2015) . Pharmacoeconomics.
  • Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R, Pavord I, Everard M & Lawson R (2015) . Health Technology Assessment, 19(82).
  • Campbell F, Holmes M, Everson-Hock E, Davis S, Woods HB, Anokye N, Tappenden P & Kaltenthaler E (2015) . Health Technology Assessment, 19(60).
  • Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2015) . Health Econ, 24(6), 742-754.
  • Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) . PharmacoEconomics, 32(12), 1171-1183.
  • Tappenden P & Chilcott J (2014) . Value in Health, 17(7), A585-A585.
  • Tappenden P & Chilcott JB (2014) . Pharmacoeconomics, 32(10), 967-979.
  • Ciani O, Cantrell A, Davis S, Tappenden P, Saad ED, Garside R, Buyse M, Stein K & Taylor RS (2014) . International Journal of Technology Assessment in Health Care, 30(3), 312-324.
  • Kaltenthaler E, Essat M, Tappenden P & Paisley S (2014) . International Journal of Technology Assessment in Health Care, 30(3), 333-340.
  • Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C & Brownlee K (2014) . PHARMACOECONOMICS, 32(2), 159-172.
  • Uttley L & Tappenden P (2014) . Current Opinion in Pulmonary Medicine, 20(6), 607-612.
  • Stevenson M, Tappenden P & Squires H (2014) . International Journal of Systems Science, 45(1), 60-68.
  • Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S , Mavranezouli I et al (2013) . Health Technol Assess, 17(58), v-192.
  • Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C & Cantrell A (2013) . Health Technol Assess, 17(56), v-181.
  • Uttley L, Harnan S, Cantrell A, Taylor C, Walshaw M, Brownlee K & Tappenden P (2013) . Eur Respir Rev, 22(130), 476-486.
  • Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A & Cantrell A (2013) . BMJ Open, 3(11), e003573.
  • Asaria M, Griffin S, Cookson R, Tappenden P & Whyte S (2013) . VALUE IN HEALTH, 16(7), A426-A426.
  • Kaltenthaler E, Tappenden P & Paisley S (2013) . Value in Health, 16(5), 830-836.
  • Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) . Value in Health.
  • Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P & Hyde C (2013) . Health Technol Assess, 17(14), 1-237.
  • Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JPD & Bakhai A (2013) . Pharmacoeconomics, 31(4), 269-275.
  • Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) . BMC Health Serv Res, 13, 105.
  • Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) . Value Health, 15(8), 1127-1136.
  • Tappenden P, Campbell F, Rawdin A, Wong R & Kalita N (2012) . Health Technol Assess, 16(20), 1-72.
  • Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2012) . Br J Cancer, 106(5), 805-816.
  • Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2012) Assessing the costs and benefits of a pharmacogenetic test to reduce the incidence of adverse events. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 21(1), 118-118.
  • Delea TE, Tappenden P, Sofrygin O, Browning D, Amonkar MM, Karnon J, Walker MD & Cameron D (2012) . Eur J Health Econ, 13(5), 589-603.
  • Tilson L, Sharp L, Usher C, Walsh C, Whyte S, O'Ceilleachair A, Stuart C, Mehigan B, Kennedy MJ, Tappenden P , Chilcott J et al (2012) . European Journal of Health Economics, 13(4), 511-524.
  • Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2011) . VALUE IN HEALTH, 14(7), A251-A252.
  • Shabaruddin FH, Elliott RA, Tappenden P & Payne K (2011) . VALUE IN HEALTH, 14(7), A252-A252.
  • Squires H, Tappenden P, Cooper K, Carroll C, Logan R & Hind D (2011) . Clinical Therapeutics, 33(9), 1289-1305.
  • Whyte S, Walsh C & Chilcott J (2011) . Medical Decision Making, 31(4), 625-641.
  • Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC & Nicholson KG (2011) . J Infect, 62(1), 14-25.
  • Papaioannou D, Cooper KL, Carroll C, Hind D, Squires H, Tappenden P & Logan RF (2011) . Colorectal Dis, 13(10), 1085-1099.
  • Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) . Int J Technol Assess Health Care, 26(4), 362-369.
  • Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J & Tappenden J (2010) . International Journal of Technology Assessment in Health Care, 26(4), 362-369.
  • McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N & Abrams K (2010) . BMJ, 340, c1786.
  • Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D & Tappenden P (2010) . Health Technol Assess, 14(32), 1-206.
  • Sofrygin O, Delea TE, Tappenden P, Karnon J, Browning D, Amonkar M, Lykopoulos K & Cameron DA (2010) . JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  • Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H & Tappenden P (2010) . CLIN THER, 32(5), 789-803.
  • Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A (2010) . Health Technol Assess, 14(25), iii-107.
  • Oakley JE, Brennan A, Tappenden P & Chilcott J (2010) . J Health Econ, 29(3), 468-477.
  • Carroll C, Cooper K, Papaioannou D, Hind D, Tappenden P, Pilgrim H & Booth A (2010) . Aliment Pharmacol Ther, 31(7), 708-718.
  • Madan J, Rawdin A, Stevenson M & Tappenden P (2010) . Value Health, 13(2), 215-221.
  • Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) . Bone Marrow Transplant, 45(6), 1014-1021.
  • Kerner JF, Cazap E, Yach D, Pierotti MA, Daidone MG, De Blasio P, Geary P, Schacter B, Sant M, Habbema JDF , Sankaranarayanan R et al (2009) . Tumori, 95(5), 610-622.
  • Pilgrim H, Tappenden P, Chilcott J, Bending M, Trueman P, Shorthouse A & Tappenden J (2009) . J OPER RES SOC, 60(10), 1305-1314.
  • Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) . Int J Technol Assess Health Care, 25(4), 470-478.
  • Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Comber H & Barry M (2009) COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND. VALUE HEALTH, 12(7), A280-A280.
  • Whyte S, Walsh C, Sharp L, O'Ceilleachair A, Tilson L, Usher C, Chilcott J, Tappenden P, Staines A, Comber H & Barry M (2009) . Value in Health, 12(7), A395-A395.
  • Hind D, Tappenden P, Peters J & Kenjegalieva K (2009) . Health Technol Assess, 13 Suppl 2, 9-13.
  • Delea T, Sofrygin O, Tappenden P, Browning D, Amonkar MM, Karnon J & Lykopoulos K (2009) COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT). VALUE HEALTH, 12(3), A49-A49.
  • Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R & Nicholson K (2009) . Health Technol Assess, 13(11), iii-246.
  • Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G, Chilcott JB , Tappenden P et al (2009) . BMC Neurol, 9, 1.
  • Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD & Brown M (2009) . Value Health, 12(5), 657-665.
  • Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J, Thomas N, Pratt P, Freeman-Parry L, Karsh B-T , Gandhi T et al (2008) . J Health Serv Res Policy, 13(2), 85-91.
  • Parkin DM, Tappenden P, Olsen AH, Patnick J & Sasieni P (2008) . J Med Screen, 15(4), 163-174.
  • Garthwaite PH, Chilcott JB, Jenkinson DJ & Tappenden P (2008) . Int J Technol Assess Health Care, 24(3), 350-357.
  • DeLea T, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge HJ & Walker MD (2008) Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with HER2+ metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151.. J Clin Oncol, 26(15_suppl), 6559.
  • DeLea T, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge HJ & Walker MD (2008) . JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  • Sofrygin O, Delea T, Tappenden P, Karnon J, Amonkar MM & Walker M (2008) Validity of proportional hazards (PH) Weibull models for analyzing progression free survival (PFS) and overall survival (OS) in patients with trastuzumab (TZ)-refractory ERBB2+(HER2+) metastatic breast cancer (MBC) receiving lapatinib plus capecitabine (L+C) versus capecitabine only (C-only). VALUE HEALTH, 11(3), A57-A57.
  • Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P & Ryan A (2008) . Health Technol Assess, 12(15), iii-162.
  • Kaltenthaler E, Tappenden P, Booth A & Akehurst R (2008) . Health Policy, 87(3), 389-400.
  • Tappenden P, Brazier J, Ratcliffe J & Chilcott J (2007) . Pharmacoeconomics, 25(8), 685-693.
  • Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes.. Health technology assessment (Winchester, England), 11(52).
  • Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes.. Health technology assessment (Winchester, England), 11(52).
  • Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J & Madan J (2007) A review and critique of modelling in prioritising and designing screening programmes. HEALTH TECHNOL ASSES, 11(52), 1-+.
  • Tappenden P, Jones R, Paisley S & Carroll C (2007) . Eur J Cancer, 43(17), 2487-2494.
  • Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J, Thomas N, Pratt P, Freeman-Parry L, Karsh BT , Gandhi T et al (2007) . SAFETY SCI, 45(4), 523-539.
  • Tappenden P, Jones R, Paisley S & Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.. Health technology assessment (Winchester, England), 11(12).
  • Tappenden P, Jones R, Paisley S & Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.. Health technology assessment (Winchester, England), 11(12).
  • Tappenden P, Jones R, Paisley S & Carroll C (2007) . Health Technol Assess, 11(12), 1-iv.
  • Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H & Karnon J (2007) . Gut, 56(5), 677-684.
  • Pandor A, Eggington S, Paisley S, Tappenden P & Sutcliffe P (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 10(41).
  • Pandor A, Eggington S, Paisley S, Tappenden P & Sutcliffe P (2006) . Health Technol Assess, 10(41), iii-185.
  • Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P & Chilcott J (2006) . Br J Cancer, 95(9), 1195-1201.
  • Tappenden P, Chilcott J, Ward S, Eggington S, Hind D & Hummel S (2006) . Eur J Cancer, 42(17), 2867-2875.
  • Chilcott J, Tappenden P, Lloyd Jones M, Wight J, Forman K, Wray J & Beverley C (2004) . BJOG, 111(9), 903-907.
  • Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P & Beverley C (2004) . BJOG, 111(9), 892-902.
  • Tappenden P, Chilcott JB, Eggington S, Oakley J & McCabe C (2004) . Health Technol Assess, 8(27), iii-78.
  • Chilcott J, Brennan A, Booth A, Karnon J & Tappenden P (2003) The role of modelling in prioritising and planning clinical trials.. Health technology assessment (Winchester, England), 7(23).
  • Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH & Cost Effectiveness of Multiple Sclerosis Therapies Study Group (2003) . BMJ, 326(7388), 522.
  • Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C & Tappenden P (2003) . Health Technol Assess, 7(4), iii-62.
  • Richards RG, Sampson FC, Beard SM & Tappenden P (2002) . Health Technology Assessment, 6(10).
  • Chilcott J, Wight J, Jones ML & Tappenden P (2001) . Health Technology Assessment, 5(19).
  • Chilcott J, Tappenden P, Jones ML & Wight JP (2001) . Clin Ther, 23(11), 1792-1823.
  • Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N () . PharmacoEconomics.
  • Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS () . PharmacoEconomics.
  • Hind D, Tappenden P, Peters J & Kenjegalieva K () . Health Technology Assessment, 13(Suppl 2), 9-13.

Book chapters

  • Tappenden P (2014) , Encyclopedia of Health Economics (pp. 168-179). Elsevier

Conference proceedings

  • Ren S, Singh J, Gsteiger S, Reed B, Cogley CM, Abrams K, Dawoud D, Owen R, Tappenden P, Quinn T & Bujkiewicz S (2024) EVALUATING AMYLOID-BETA AS A SURROGATE ENDPOINT FOR COGNITIVE FUNCTION IN ALZHEIMER'S DISEASE: A BAYESIAN HIERARCHICAL META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF ANTI-AMYLOID MONOCLONAL ANTIBODIES. VALUE IN HEALTH, Vol. 27(12) (pp S623-S623)
  • Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S134-S134)
  • Lister J, Paisley S, Tappenden P & Carroll C (2023) IDENTIFICATION OF HEALTH STATE UTILITY VALUES FOR HEALTH ECONOMIC MODELS: EMPIRICAL TESTING OF ALTERNATIVE SEARCH METHODS. VALUE IN HEALTH, Vol. 26(12) (pp S174-S175)
  • Wheaton L, Poad H, Tappenden P & Bujkiewicz S (2023) BAYESIAN META-ANALYSIS OF DATA FROM TRIALS OF MIXED PATIENT POPULATIONS TO INFORM HEALTH ECONOMIC MODELS FOR PATIENTS HARBORING A PREDICTIVE BIOMARKER. VALUE IN HEALTH, Vol. 26(12) (pp S425-S425)
  • Lister J, Paisley S, Tappenden P & Carroll C (2023) A SCOPING REVIEW OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) AND HEALTH ECONOMIC (HE) MODELLING GUIDELINES FOR IDENTIFICATION OF HEALTH ECONOMIC MODEL INPUTS. VALUE IN HEALTH, Vol. 26(12) (pp S375-S375)
  • Alshreef A, Latimer N, Tappenden P, McKane W, Hughes DA & Dixon S (2022) A METHODOLOGICAL FRAMEWORK TO ACCOUNT FOR THE IMPACT OF NON-ADHERENCE ON THE COST-EFFECTIVENESS OF CHRONIC MEDICATIONS. VALUE IN HEALTH, Vol. 25(7) (pp S520-S520)
  • Alshreef A, Latimer N, Tappenden P, McKane W, Fotheringham J & Dixon S (2022) A CASE STUDY ASSESSING THE COST-EFFECTIVENESS OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANTATION IN ADULTS: ACCOUNTING FOR NON-ADHERENCE USING DATA FROM A RANDOMISED TRIAL AND THE REAL WORLD WITHIN A DECISION-ANALYTIC MODEL. VALUE IN HEALTH, Vol. 25(7) (pp S529-S529)
  • Srivastava T, Latimer NR & Tappenden P (2020) ESTIMATION OF TRANSITION PROBABILITIES FOR STATE-TRANSITION MODELS: A REVIEW OF NICE APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S615-S616)
  • Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 29 November 2018.
  • Tappenden P, Wang Y, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D, Sharrack B & Snowden J (2017) Evaluating the cost-effectiveness of autologous haematopoietic stem cell transplantation (aHSCT) versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (MAIC). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S41-S41)
  • Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, Tappenden P & Woolacott N (2016) . Value in Health, Vol. 19(7) (pp A490-A490)
  • Carroll C, Kaltenthaler E, Tappenden P, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M & Woolacott N (2016) . Value in Health, Vol. 19(7) (pp A468-A469)
  • Goodall M, Tosh J, Alshreef AO & Tappenden P (2016) . Value in Health, Vol. 19(7)
  • Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M (2015) . Value in Health, Vol. 18(7) (pp A345-A345)
  • Tappenden P, Harnan S, Uttley L, Mildred M, Taylor CJ, Brownlee K & Walshaw M (2013) . Value in Health, Vol. 16(7) (pp A372-A372)
  • Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad E, Buyse M & Taylor R (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
  • Harnan SE, Uttley L, Cantrell A, Taylor CJ, Walshaw M, Brownlee K & Tappenden P (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A367-A367)
  • Kaltenthaler E, Rathbone J, Tappenden P, Bessey A & Cantrell A (2012) . VALUE IN HEALTH, Vol. 15(7) (pp A455-A455)
  • Tappenden P, Brennan A, Chilcott J & Squires H (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
  • Tappenden P, Brennan A, Chilcott J & Squires H (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
  • Delea TE, Tappenden P, Sofrygin O, Karnon J, Amonkar M, Browning D, Rudge H & Walker M (2007) Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective. EJC SUPPLEMENTS, Vol. 5(4) (pp 225-225)

Scholarly editions

  • Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P & Wailoo A A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence.

Posters

  • Rathbone J, Kaltenthaler E, Tappenden P, Bessey A & Cantrell A Issues in the systematic review of drugs for rare diseases: A case study of Eculizumab for AHUS (2012).
  • Harnan S, Essat M, Gomersall T, Tappenden P, Wong R, Lawson R, Pavord I & Everard M Exhaled nitric oxide for the diagnosis of asthma in children and adults: a systematic review.
  • Kaltenhaler E, Tappenden P & Paisley S Reviewing the evidence used in cost-effectiveness models in health technology assessment: a qualitative investigation of current concerns and future research priorities.
  • Tappenden P, Brennan A, Chilcott J & Squires H Using Whole Disease Modelling to inform economic recommendations for the detection, diagnosis, treatment and followup of colorectal cancer.

Preprints

  • Ren S, Singh J, Gsteiger S, Cogley C, Reed B, Abrams KR, Dawoud D, Owen RK, Tappenden P, Quinn TJ & Bujkiewicz S (2025) , arXiv.
  • Umemneku-Chikere CM, Wheaton L, Poad H, Ray D, Andrade IC, Khan S, Tappenden P, Abrams KR, Owen RK & Bujkiewicz S (2023) , arXiv.
Teaching activities
  • I am module lead for HAR691 (Using evidence in the design and development of models)
  • I am an active PhD supervisor (3 current PhD students)
Professional activities and memberships

I am the Director of Modelling for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit (DSU). I am a member of NICE Technology Appraisal Committee C.

Links